Current Rheumatology Reports最新文献_第4页

Erosive Hand Osteoarthritis: Recent Advances and Future Treatments. 侵蚀性手部骨关节炎：最新进展与未来治疗。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-04-01 Epub Date: 2024-01-12 DOI: 10.1007/s11926-023-01130-9

Marta B Bean, Marta Favero, Roberta Ramonda, Carla R Scanzello

{"title":"Erosive Hand Osteoarthritis: Recent Advances and Future Treatments.","authors":"Marta B Bean, Marta Favero, Roberta Ramonda, Carla R Scanzello","doi":"10.1007/s11926-023-01130-9","DOIUrl":"10.1007/s11926-023-01130-9","url":null,"abstract":"Purpose of the review: Erosive hand osteoarthritis (EHOA) is an aggressive form of hand osteoarthritis that leads to significant disability, and recent data suggests that it is increasing in prevalence. This review provides an update of our current understanding of epidemiology, genetic associations, biomarkers, pathogenesis, and treatment of EHOA, with particular focus on studies published within the last 5 years.Recent findings: New studies of EHOA have identified new genetic loci associated with disease, including variants in genes involved in inflammation and bone remodeling. Preclinical studies implicate pathways of innate immunity, including some that may be causal in the condition. Recent novel studies showed that inflammatory features identified by ultrasound and MRI are associated with development of erosive lesions over time on conventional radiography. In the future, these imaging modalities may be useful in identifying patients at risk of adverse outcomes. Promising new findings in genetics, biomarkers, and treatment targets will hopefully allow for future therapeutic options for this debilitating condition.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"103-111"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broadening the Scope of Resilience in Chronic Pain: Methods, Social Context, and Development. 拓宽慢性疼痛的复原力范围：方法、社会背景和发展。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.1007/s11926-024-01133-0

John A Sturgeon, Caroline Zubieta, Chelsea M Kaplan, Jennifer Pierce, Anne Arewasikporn, P Maxwell Slepian, Afton L Hassett, Zina Trost

{"title":"Broadening the Scope of Resilience in Chronic Pain: Methods, Social Context, and Development.","authors":"John A Sturgeon, Caroline Zubieta, Chelsea M Kaplan, Jennifer Pierce, Anne Arewasikporn, P Maxwell Slepian, Afton L Hassett, Zina Trost","doi":"10.1007/s11926-024-01133-0","DOIUrl":"10.1007/s11926-024-01133-0","url":null,"abstract":"Purpose of review: A wellspring of new research has offered varying models of resilience in chronic pain populations; however, resilience is a multifaceted and occasionally nebulous construct. The current review explores definitional and methodological issues in existing observational and clinical studies and offers new directions for future studies of pain resilience.Recent findings: Definitions of pain resilience have historically relied heavily upon self-report and from relatively narrow scientific domains (e.g., positive psychology) and in narrow demographic groups (i.e., Caucasian, affluent, or highly educated adults). Meta-analytic and systematic reviews have noted moderate overall quality of resilience-focused assessment and treatment in chronic pain, which may be attributable to these narrow definitions. Integration of research from affiliated fields (developmental models, neuroimaging, research on historically underrepresented groups, trauma psychology) has the potential to enrich current models of pain resilience and ultimately improve the empirical and clinical utility of resilience models in chronic pain.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"112-123"},"PeriodicalIF":5.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microbial Mechanisms of Rheumatoid Arthritis Pathogenesis. 类风湿性关节炎发病的微生物机制。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-04-01 Epub Date: 2024-02-01 DOI: 10.1007/s11926-024-01135-y

Brenda J Seymour, Brendan E Allen, Kristine A Kuhn

引用次数: 0

Paediatric Rheumatology Fails to Meet Current Benchmarks, a Call for Health Equity for Children Living with Juvenile Idiopathic Arthritis, Using Digital Health Technologies 儿科风湿病学未能达到当前基准，呼吁利用数字健康技术实现幼年特发性关节炎患儿的健康平等

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-11 DOI: 10.1007/s11926-024-01145-w

Sonia Butler, Dean Sculley, Derek Santos, Xavier Girones, Davinder Singh-Grewal, Andrea Coda

{"title":"Paediatric Rheumatology Fails to Meet Current Benchmarks, a Call for Health Equity for Children Living with Juvenile Idiopathic Arthritis, Using Digital Health Technologies","authors":"Sonia Butler, Dean Sculley, Derek Santos, Xavier Girones, Davinder Singh-Grewal, Andrea Coda","doi":"10.1007/s11926-024-01145-w","DOIUrl":"https://doi.org/10.1007/s11926-024-01145-w","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3>This critical review begins by presenting the history of Juvenile Idiopathic Arthritis (JIA) management. To move the conversation forward in addressing the current shortcomings that exist in the clinical management of children living with JIA, we argue that to date, the advancement of successful treatments for JIA has been historically slow. Factors implicated in this situation include a lack of rigorous research, JIA being considered a rare disease, and JIA’s idiopathic and complex pathophysiology.<h3 data-test=\"abstract-sub-heading\">Recent Findings</h3>Despite the well-intended legislative changes to increase paediatric research, and the major advancements seen in molecular medicine over the last 30 years, globally, paediatric rheumatology services are still failing to meet the current benchmarks of best practice. Provoking questions on how the longstanding health care disparities of poor access and delayed treatment for children living with JIA can be improved, to improve healthcare outcomes.<h3 data-test=\"abstract-sub-heading\">Summary</h3>Globally, paediatric rheumatology services are failing to meet the current benchmarks of best practice. Raising awareness of the barriers hindering JIA management is the first step in reducing the current health inequalities experienced by children living with JIA. Action must be taken now, to train and well-equip the paediatric rheumatology interdisciplinary workforce. We propose, a resource-efficient way to improve the quality of care provided could be achieved by embedding digital health into clinical practice, to create an integrative care model between the children, general practice and the paediatric rheumatology team. To improve fragmented service delivery and the coordination of interdisciplinary care, across the healthcare system.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"34 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140098199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pipeline Therapies for Gout. 痛风的管线疗法。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-22 DOI: 10.1007/s11926-023-01128-3

Kevin Yip, Genna Braverman, Linda Yue, Theodore Fields

{"title":"Pipeline Therapies for Gout.","authors":"Kevin Yip, Genna Braverman, Linda Yue, Theodore Fields","doi":"10.1007/s11926-023-01128-3","DOIUrl":"10.1007/s11926-023-01128-3","url":null,"abstract":"Purpose of review: Despite effective available treatments, gout management is often unsuccessful in getting patients to target serum urate goal and in managing flares in the setting of comorbidities. Studies addressing future treatment options for short- and long-term management are reviewed.Recent findings: URAT-1 blocking agents have been helpful but have had limitations related to effects on renal function, lack of efficacy with renal impairment, and potential to increase renal stones. Dotinurad may function in the setting of decreased renal function. Arhalofenate has anti-URAT-1 activity and may also blunt gout flares. A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study. New uricase treatments manufactured in combination with agents that can reduce immunogenicity may make uricase treatment simpler. A unique strategy of inhibiting gut uricase may offer the benefits of avoiding systemic absorption. For gout flares, IL-1β inhibitor studies in progress include different dosing schedules. Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"69-80"},"PeriodicalIF":5.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temperature-Mediated Neural Interventions in Knee Osteoarthritis: a Review of Cryoneurolysis and Cooled Radiofrequency Ablation with Ultrasound Guidance. 膝关节骨性关节炎的温控神经干预：超声引导下的冷冻神经溶解术和冷却射频消融术综述。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-21 DOI: 10.1007/s11926-023-01127-4

Christopher M Tidwell, Paul J DeMarco

{"title":"Temperature-Mediated Neural Interventions in Knee Osteoarthritis: a Review of Cryoneurolysis and Cooled Radiofrequency Ablation with Ultrasound Guidance.","authors":"Christopher M Tidwell, Paul J DeMarco","doi":"10.1007/s11926-023-01127-4","DOIUrl":"10.1007/s11926-023-01127-4","url":null,"abstract":"Purpose of review: Knee osteoarthritis is a debilitating chronic disease affecting nearly half of the world's population at some point in their lives. Treatment of pain and loss of function associated with this disease has been limited. In this review, we seek to explore how neural interventions with ultrasound guidance may be an emerging option for non-pharmacologic pain relief in patients with knee osteoarthritis.Recent findings: Cryoneurolysis techniques have been demonstrated to provide pain relief out to 150 days post-treatment in knee osteoarthritis in select individuals. There have also been studies of cryoneurolysis pre-operatively to total knee replacement providing reduced pain, reduced opioid use post-operatively, and shorter hospital length of stay. Cooled radiofrequency ablation (CRFA) has been demonstrated to significantly reduce pain, improve functionality, and reduce pharmacologic needs in knee osteoarthritis out to 2 years. Both interventions appear to have increased accuracy with ultrasound, and CRFA appears to be associated with improved patient outcomes. The research demonstrates the efficacy of both cryoneurolysis and cooled radiofrequency ablation in the treatment of knee osteoarthritis. Ultrasound guidance in neurolysis provides an additional tool with real-time, high-accuracy nerve localization. These therapies should be considered for certain patients to assist in pain management in the non-operative and post-operative phase of knee osteoarthritis management. Further research is needed to further define the long-term effects and the long-term utility of the techniques in knee pain.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"89-95"},"PeriodicalIF":5.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138828608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twenty Years of SPARTAN: From Inception to Impact (SPARTAN 2023 Annual Meeting Proceedings). SPARTAN 20 年：从开始到影响（SPARTAN 2023 年年会论文集）。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-12 DOI: 10.1007/s11926-023-01131-8

Joerg Ermann, Atul Deodhar, Muhammad Asim Khan, Michael H Weisman, John D Reveille

引用次数: 0

Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review. 青少年皮肌炎中的钙质沉着——流行病学、发病机制、临床特征和治疗:系统综述。

IF 5 2区医学

Current Rheumatology Reports Pub Date : 2024-02-01 Epub Date: 2023-12-07 DOI: 10.1007/s11926-023-01126-5

Jucier Gonçalves Júnior, Samuel Katsuyuki Shinjo

{"title":"Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review.","authors":"Jucier Gonçalves Júnior, Samuel Katsuyuki Shinjo","doi":"10.1007/s11926-023-01126-5","DOIUrl":"10.1007/s11926-023-01126-5","url":null,"abstract":"Purpose of review: We performed a systematic review of the literature on the epidemiology, pathogenesis, clinical and laboratory characterization, and treatment of calcinosis in patients with juvenile dermatomyositis (JDM). A qualitative systematic review was conducted from January 1975 to April 2023 according to the PRISMA protocol using three electronic databases: PubMed, Web of Science, and Scopus. Studies were analyzed based on the following eligibility criteria: at least one combination of the terms described in the search strategy appeared in the title, written in English, Portuguese, or Spanish, and addressed the epidemiology, pathogenesis, diagnosis, and treatment of calcinosis in juvenile dermatomyositis. Systematic or scoping reviews, letters, clinical images, book chapters, abstracts, inflammatory myopathy in other connective tissue diseases, idiopathic inflammatory myopathies in adults, and purely qualitative studies were excluded.Recent findings: Seventy-five studies were included. According to the literature, calcinosis is common in women, around five years old, with three years of disease in association with osteoarticular, cutaneous, pulmonary manifestations, and fever. The pathogenesis is still unknown, but the participation of interleukin 1 and 6, tumor necrosis factor alpha, and innate immunity dysregulation seem to be involved. Common autoantibodies are anti-NXP-2, anti-MDA-5, and anti-Mi-2, and their treatment remains controversial. Prospective, randomized, controlled studies are needed to evaluate treatment protocols and map the natural history of this serious complication. Calcinosis seems to be more common in White female children with muscle weakness, fever, arthritis, severe pulmonary, and skin involvement with anti-NXP-2, anti-MDA-5, and anti-Mi-2 autoantibodies. The multitargets and aggressive treatment is recommended.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"53-68"},"PeriodicalIF":5.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of IFN-α in Rheumatoid Arthritis. IFN-α 在类风湿关节炎中的作用

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-02-01 Epub Date: 2023-12-05 DOI: 10.1007/s11926-023-01125-6

Chung M A Lin, John D Isaacs, Faye A H Cooles

{"title":"Role of IFN-α in Rheumatoid Arthritis.","authors":"Chung M A Lin, John D Isaacs, Faye A H Cooles","doi":"10.1007/s11926-023-01125-6","DOIUrl":"10.1007/s11926-023-01125-6","url":null,"abstract":"Purpose of review: Type 1 interferons (IFN-I) are of increasing interest across a wide range of autoimmune rheumatic diseases. Historically, research into their role in rheumatoid arthritis (RA) has been relatively neglected, but recent work continues to highlight a potential contribution to RA pathophysiology.Recent findings: We emphasise the importance of disease stage when examining IFN-I in RA and provide an overview on how IFN-I may have a direct role on a variety of relevant cellular functions. We explore how clinical trajectory may be influenced by increased IFN-I signalling, and also, the limitations of scores composed of interferon response genes. Relevant environmental triggers and inheritable RA genetic risk relating to IFN-I signalling are explored with emphasis on intriguing data potentially linking IFN-I exposure, epigenetic changes, and disease relevant processes. Whilst these data cumulatively illustrate a likely role for IFN-I in RA, they also highlight the knowledge gaps, particularly in populations at risk for RA, and suggest directions for future research to both better understand IFN-I biology and inform targeted therapeutic strategies.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"37-52"},"PeriodicalIF":5.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10787895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138486919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions. 类风湿关节炎的多发病:文献综述及未来发展方向。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-01-01 Epub Date: 2023-11-23 DOI: 10.1007/s11926-023-01121-w

Jonathan Katz, Christie M Bartels

{"title":"Multimorbidity in Rheumatoid Arthritis: Literature Review and Future Directions.","authors":"Jonathan Katz, Christie M Bartels","doi":"10.1007/s11926-023-01121-w","DOIUrl":"10.1007/s11926-023-01121-w","url":null,"abstract":"Purpose of review: To offer a narrative review of literature and an update on rheumatoid arthritis (RA) multimorbidity research over the past five years as well as future directions.Recent findings: Patients with RA experience higher prevalence of multimorbidity (31-86% vs 18-71% in non-RA) and faster accumulation of comorbidities. Patients with multimorbidity have worse outcomes compared to non-RA multimorbid patients and RA without multimorbidity including mortality, cardiac events, and hospitalizations. Comorbid disease clusters often included: cardiopulmonary, cardiometabolic, and depression and pain-related conditions. High-frequency comorbidities included interstitial lung disease, asthma, chronic obstructive pulmonary disease, cardiovascular disease, fibromyalgia, osteoarthritis, and osteoporosis, thyroid disorders, hypertension, and cancer. Furthermore, patients with RA and multimorbidity are paradoxically at increased risk of high RA disease activity but experience a lower likelihood of biologic use and more biologic failures. RA patients experience higher prevalence of multimorbidity and worse outcomes versus non-RA and RA without multimorbidity. Findings call for further studies.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"24-35"},"PeriodicalIF":5.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138294794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0